UPDATE: Credit Suisse Reiterates on Envision Healthcare as Growth Opportunities Remain Abundant

In a report published Thursday, Credit Suisse analyst Ralph Giacobbe reiterated a Neutral rating on Envision Healthcare (NYSE: EVHC), and raised the price target from $29.00 to $36.00.

In the report, Credit Suisse noted, “EVHC reported 4Q13 adjusted EBITDA of $127M and EPS of $0.23, in line with its preannouncement from early January. The company also reaffirmed its 2014 EBITDA guidance of $538M-$545M and adjusted EPS of $1.10-$1.15, which does not include any reform benefit. The company continues to post strong growth with new contracts driving EmCare and AMR revenue growth. Management remains upbeat on future revenue opportunities with sources of growth from new contracts, acquisitions, expanding service lines, same contract, healthcare reform, and Evolution Health. We are raising our target price to $36 (from $29); maintain Neutral rating on valuation.”

Envision Healthcare closed on Wednesday at $33.68.